| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6190624 | Cancer Treatment Reviews | 2014 | 8 Pages |
Abstract
New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mariano Provencio, Antonio Sánchez, Margarita Sánchez-Beato,